sovaprevir
Small moleculeexperimental
Sovaprevir is an experimental drug designed to treat the hepatitis C virus. It is under development by Achillion Pharmaceuticals. It acts as a NS3/4A inhibitor. Sovaprevir received fast track status from the U.S. Food and Drug Administration in 2012. — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2010 (NCT01180790)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
Hepatitis C virus serine protease, NS3/NS4A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](CC(=O)N1CCCCC1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1- Mol. weight
- 799.99 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSovaprevir ↗
- ChEMBLCHEMBL2105750 ↗
Also known as
- ach-0141625
- ach-0141625
- sovaprevir
- sovaprevir
- sovaprevir
- sovaprevir
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01849562 | Phase 2 | Apr 1, 2013 | Achillion Pharmaceuticals |
| NCT01180790 | Phase 2 | Sep 1, 2010 | Achillion Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Achillion Pharmaceuticals | For profit | 2 | 2 | 1 | 2010 |
1 organizations
Page 1 / 1